| Old Articles: <Older 6361-6370 Newer> |
|---|
 |
The Motley Fool
March 17, 2005
Travers & Mock |
Stock Madness 2005: Geron vs. UTStarcom Biotech faces off against telecom in this contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness. -- which company gets your vote?   |
The Motley Fool
March 17, 2005
Brokamp & Simpson |
Stock Madness 2005: General Electric vs. ABB In this contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness, will older and wiser prevail? Or will a growing turnaround opportunity win the day ? |
The Motley Fool
March 17, 2005
Robert Brokamp |
Stocks for the Really Long Term Yes, stocks are the long-term investment of choice. But at any price? |
The Motley Fool
March 17, 2005
Stephen D. Simpson |
GM Sputters Again Can this American giant turn things around, or is the latest news just another gurgle on its way to oblivion? The problems at GM are legion. Stay far away from this stock. |
The Motley Fool
March 17, 2005
Simpson & Hwang |
Stock Madness 2005: Level 3 vs. WPT Enterprises In this contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness, two companies harness the power of the Internet with different goals in mind. |
The Motley Fool
March 17, 2005
Stephen D. Simpson |
Patience Rewarded at Last Amylin's battle to get Symlin approved was long and difficult, but success will have its rewards. Should investors take a shot? |
The Motley Fool
March 17, 2005
Mann & Smith |
Stock Madness 2005: Apple vs. Microsoft Two computer powerhouses fight for victory in this contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness. |
The Motley Fool
March 17, 2005
Tim Beyers |
Verizon's Qwest in Peril? Troubled telco Qwest makes one more bid for MCI. Will Verizon up its offer? Investors, take note. |
The Motley Fool
March 17, 2005
Jeremy MacNealy |
A Stock With Bark and Bite Petco posts strong results. At the current valuation, potential investors will want to look for a discounted price on this stock. |
The Motley Fool
March 17, 2005
Stephen D. Simpson |
(G)Nashing of Teeth at Kensey Lower guidance and slower-than-expected FDA approval of TriActiv continue to bedevil this medical device maker. |
| <Older 6361-6370 Newer> Return to current articles. |
